ProtAffin Biotechnologie, AG: Series B €4.0M

ProtAffin Biotechnologie (Austria) is focused on developing novel biotechnology therapeutic products for acute and chronic inflammatory diseases has closed a €4.0M Series A financing. Participants include The Entrepreneurs Fund BV, Aescap Venture Management and Z-Cube.

ProFibrix B.V.: Series A €8.5M

ProFibrix (Netherlands) a biotech company focused on fibrinogen-based products to stop surgical hemmoraging and initiate tissue repair, has closed a €8.5M Series A round. The deal was led by Index Ventures.

Affinium Pharma, Inc.: Series A $18M

Affinium Pharmaceuticals (Canada) who is developing a new class of antibiotics targeting staph infections closed an $18M Series A financing. The deal was lead by Forward Ventures along with Oxford Bioscience , SV Life Sciences and Genesys Capital Partners.

Nitec Pharma AG.: Series B $26M

Nitec Pharma (Switzerland) a drug company focused on the treatment of chronic inflammatory diseases with lead indications in Rheumatoid Arthritis and Polymylagia Rheumatica, raised $26M Series B round. The deal was led by NGN Capital other participants included Atlas Venture and Global Life Science Ventures.

Okairos AG: Series A €7.2M

Okairos (Switzerland) a biopharmaceutical company using adenovirus-based technology to focus on T-cell vaccines has closed a €7.2M Series A financing. The deal was led by Life Science Partners and Biomedinvest and was joined by the Novartis Venture Fund.

PainCeptor Pharma Corp: Series B $20.8M

PainCeptor (Canada) a drug company focused on the treatment of chronic and acute pain raised a $20.8M Series B round. The deal was lead by Desjardins Venture Capital, CDP Capital, T2C2 Capital, Business Development Bank of Canada and Lothian Partners.

CoDa Therapeutics, Inc.: Series A $20M

CoDa Therapeutics (New Zeland) -based drug company focused on Nexagon, a wound care and tissue repair therapeutic, raised a $20M Series A financing. The round was led by Domain Associates and GBS Venture Partners.

Cytochroma, Inc.: Series C Cnd$21M

Cytochroma (Canada) a drug company focused on Psoriasis and chronic kidney disease raised Cnd$21M in Series C financing. Investors include VenGrowth Advanced Life Sciences Fund, Novo A/S and GeneChem Technologies Venture Fund.

Immatics Biotech, GmbH: Series B €40M

Immatics Biotechnologies (Germany) developing immunotherapies for renal cell and colorectal carcinoma raised €40 in Series B funding. Participants included Dietmar Hopp, National Technology Enterprises Co., KfW, 3i Group and Wellington Partners.

ActoGeniX, NV: Series A $26M

ActoGeniX, (Belgium) is developing a pipeline of therapeutic products based on its TopAct™ technology platform with it’s most advanced candidate for Crohn’s disease, closed a $26M Series A led by GIMV and Life Sciences Partners. New investors include Aescap, Ventech and Baekeland Fonds.